We show that increased AR expression and activity are part of the response of melanoma cells with BRAFV600 mutations to treatment with BRAF inhibitors and that increased AR expression is sufficient to render these cells resistant to these drugs, inducing transcriptional changes of BRAFi-resistant subpopulations. This evidence concerns the gene BRAF and melanoma.